Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for serious diseases. Founded in 2015, Matinas has made significant strides in the biotechnology sector, particularly in the areas of lipid-based drug delivery systems and oral formulations. The company’s flagship product, MAT2203, is a unique oral formulation of amphotericin B, designed to treat fungal infections with improved safety and efficacy. Matinas BioPharma's commitment to advancing drug delivery technologies positions it as a notable player in the biopharma industry, with a strong emphasis on enhancing patient outcomes. With a robust pipeline and strategic partnerships, Matinas continues to solidify its market position and drive innovation in the healthcare landscape.
DitchCarbon Score
How does Matinas BioPharma Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Matinas BioPharma Holdings, Inc.'s score of 18 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Matinas BioPharma Holdings, Inc.'s reported carbon emissions
Matinas BioPharma Holdings, Inc., headquartered in the US, currently does not have available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the context of the biopharmaceutical industry, it is increasingly important for companies to establish clear climate strategies and reduction goals to align with global sustainability efforts. Without specific data or commitments, it remains unclear how Matinas BioPharma is addressing its environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Matinas BioPharma Holdings, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
